TAK-003
- Business Wire
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
− Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important…
Read More » - Health
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and…
Read More » - Business
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
Osaka, Japan & Cambridge, Mass., United States: Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030 Double-Digit…
Read More » - Health
Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
Osaka, Japan: Company Aiming for Mid-Single-Digit Revenue CAGR Over Next Decade Amounting to JPY5 Trillion ($47 Billion) by FY20301 Wave…
Read More » - Business
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS
Osaka, Japan: FY2020 H1 results driven by growth of global brands (e.g. Entyvio +25.8% YOY, TAKHZYRO +45.5% YOY, NINLARO +…
Read More »